share_log
Breakings ·  Dec 9 20:32
Relmada Therapeutics Inc: Will Continue to Advance Phase 1 Study of Rel-P11, an Investigational Agent for Treatment of Metabolic Disease
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment